Mostrando 10 resultados de: 41
Publisher
Journal of Nanobiotechnology(4)
Nanomaterials(3)
Pharmaceutics(3)
Biomedicine and Pharmacotherapy(2)
Cell and Bioscience(2)
Área temáticas
Enfermedades(30)
Farmacología y terapéutica(30)
Medicina y salud(14)
Fisiología humana(13)
Ginecología, obstetricia, pediatría, geriatría(4)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(41)
ODS 10: Reducción de las desigualdades(29)
ODS 9: Industria, innovación e infraestructura(27)
ODS 2: Hambre cero(11)
ODS 12: Producción y consumo responsables(9)
Origen
scopus(41)
Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice
ArticleAbstract: Epigallocatechin-3-gallate (EGCG), a catechin found in green tea, has been previously investigated fPalabras claves:APPswe/PS1dE9 mice, Cognitive deficits, Epigallocatechin-3-gallate, hippocampus, obesity, unfolded protein responseAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Verdaguer E., Zárate C.B.Fuentes:scopusEpigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice
ArticleAbstract: Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the trPalabras claves:3-nitropropionic acid, Epigallocatechin-3-gallate, Huntington's disease, neurodegenerative diseases, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopusEpigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy
ArticleAbstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. EpigallocatePalabras claves:Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusExtracellular vesicles, the emerging mirrors of brain physiopathology
ArticleAbstract: Extracellular vesicles are secreted by a wide variety of cells, and their primary functions includePalabras claves:Alzheimer’s disease, exosomes, Extracellular vesicles, Glioblastoma, multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative diseases, Parkinson’s DiseaseAutores:Antoni Camins, Bernuz M., Boada M., Cano A., de Antonio E.E., Ettcheto M., Martí M., Pividori M.I., Puerta R., Ruíz A., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusExosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
ReviewAbstract: Neurodegenerative diseases constitute a group of pathologies whose etiology remains unknown in manyPalabras claves:exosomes, Extracellular vesicles, Nanomedicine, nanotechnology, neurodegenerative diseasesAutores:Antoni Camins, Boada M., Cano A., Ettcheto M., Muñoz-Morales Á., Ruíz A., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDevelopment and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment
ArticleAbstract: Riluzole-loaded PLGA nanoparticles (RLZ-NPs) were developed to improve the biopharmaceutical profilePalabras claves:Gellan gum, glaucoma, In situ gelling gel, PLGA nanoparticles, riluzoleAutores:Antoni Camins, Cano A., Espina M., Esteruelas G., Ettcheto M., García-Torra V., Halbaut L., Luisa García M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
ArticleAbstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low waPalabras claves:cell-penetrating peptides, Licochalcone-A, Nanoparticles, Ocular inflammation, PLGAAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Gómara M.J., Haro I., Sanchez-Lopez E.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusCurrent advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases
ReviewAbstract: Effective intervention is essential to combat the coming epidemic of neurodegenerative (ND) diseasesPalabras claves:brain disorders, Brain targeting, CNS nanomedicine, neurodegenerative diseases, neurological diseases, Polymeric nanoparticlesAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Lopez-Machado A.L., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopusCurrent applications of nanoemulsions in cancer therapeutics
ReviewAbstract: Nanoemulsions are pharmaceutical formulations composed of particles within a nanometer range. They pPalabras claves:Cáncer, Multifunctional nanoemulsions, Targeted deliveryAutores:Antoni Camins, Cano A., Dias-Ferreira J., Espina M., Ettcheto M., García M.L., Guerra M., Lopez-Machado A.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopus